Feedback
We’d love to hear your feedback on this activity. It helps us to continually improve our products.
CORRECT!
Faculty & Disclosures
Prof. Haifa Kathrin Al-Ali
University Hospital of Halle, Halle (Saale), Germany
Haifa Kathrin Al-Ali is a professor of translational oncology and the director of the Krukenberg Cancer Center at the University Hospital of Halle (Saale), Halle, Germany. read more
Prof. Al-Ali is a senior consultant in internal medicine, haematology and oncology. The scientific focus of her work has been in the field of myeloid malignancies – myeloproliferative neoplasms (MPN), myelodysplastic syndromes and acute myeloid leukaemia. Her research has focused on the implementation of phase I–IV clinical and translational studies, and the investigation of the relevance of genetic and epigenetic changes in myeloid diseases and predictive factors of response. Prof. Al-Ali’s research has been published in journals such as The New England Journal of Medicine, Blood, and Leukemia. She is also a member of the steering committee for the MPN Hub.
Prof. Haifa Kathrin Al-Ali discloses: Advisory board or panel fees from AOP Pharma, Bristol Myers Squibb, GSK, Incyte, MSD and Novartis. Consultant fees from AbbVie, AOP Pharma, Blueprint, Bristol Myers Squibb, GSK, MSD, Novartis, Otsuka and Stemline. Grants/research support from Bristol Myers Squibb and Incyte. Other financial or material support (royalties, patent, etc.) from AbbVie and Alexion.
Prof. Jean-Jacques Kiladjian
Université Paris Cité and Saint-Louis Hospital, Paris, France
Jean-Jacques Kiladjian is professor of clinical pharmacology at Université Paris Cité and consultant haematologist and head of the Clinical Investigation Center of the Saint-Louis Hospital, Paris, France. read more
Prof. Kiladjian’s research has centred on myeloproliferative neoplasms and myelodysplastic syndromes. In these disorders, he has been very active in evaluating novel therapeutics and implementing clinical trials. He is an active member of many societies including the European Hematology Association (EHA), the American Society of Hematology (ASH), the European LeukemiaNet and the European School of Haematology. Since 2008, Prof. Kiladjian has been the president of the French Intergroup of Myeloproliferative disorders. He has provided educational lectures in several French and international meetings over the years, including at ASH, EHA and the American Society of Clinical Oncology annual meetings. He is published in many peer-reviewed journals, including The New England Journal of Medicine, Journal of Clinical Oncology, Blood, Lancet Haematology, Leukemia, etc., and has authored several book chapters. He is associate editor of Leukemia, European Journal of Haematology, HemaSphere, Hemato.
Prof. Jean-Jacques Kiladjian discloses: Advisory board or panel fees from AOP Health and Incyte. Consultant fees from AbbVie, Bristol Myers Squibb, GSK and Novartis.
Prof. Alessandro Vannucchi
University of Florence, Florence, Italy
Alessandro Vannucchi is a full professor of haematology, founder of the Center Research and Innovation of Myeloproliferative Neoplasms and director of the haematology and oncology departments at the University of Florence and Azienda Ospedaliera Universitaria Careggi in Florence, Italy. read more
Prof. Vannucchi holds various appointments at the University of Florence, including director of the Postgraduate School in Hematology and director of the Center for High Education “DenoTHE”. His main research interests are myeloproliferative neoplasms (MPNs) and molecular genetics of myeloid neoplasia, including leukaemia. He has been the principal investigator of more than 70 clinical trials.
Prof. Vannucchi serves as chair of the GIMEMA Foundation Working Party on MPN and is the principal investigator of the Italian MyNERVA research alliance on MPN and related myeloid disorders. Prof. Vannucchi sits on the board of the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT), the European LeukemiaNet Work Package 9 for MPN and the European Hematology Association Specialized Working Group on Myeloproliferative Neoplasms. He is currently the president of the Italian Society of Experimental Hematology. Prof. Vannucchi has authored and co-authored more than 660 peer-reviewed publications, mostly in the field of MPN, and presented communications and invited lectures at national and international meetings.
Since 2017, Prof. Vannucchi has been listed among the Highly Cited Researchers in Clinical Medicine – Web of Science, Highly Ranked ScholarGPS, and the 100 Top Italian Scientists. In 2023, he received the honour of Commander of Merit by the President of the Republic of Italy for his scientific achievements.
Prof. Alessandro Vannucchi discloses: Advisory board or panel fees from AbbVie, AOP Orphan Pharmaceuticals, Blueprint, Bristol Myers Squibb, Celgene, Constellation, CTI BioPharma, Geron, GSK, Imago, Incyte, iOnctura, Italfarmaco, Kartos, Karyopharm, Keros, MorphoSys, Novartis, Protagonist, Roche and Sierra.
